Anthracycline followed by trastuzumab is still one of treatment options for small tumor with node-negative HER2-positive breast cancer

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. S20-S21
Author(s):  
S. Akiyoshi ◽  
K. Kobayashi ◽  
T. Kobayashi ◽  
M. Hosonaga ◽  
D. Kitagawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Options ◽  
Her2 Positive ◽  
Node Negative ◽  
Small Tumor ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

2015 ◽  
Vol 372 (2) ◽  
pp. 134-141 ◽  
Author(s):  
Sara M. Tolaney ◽  
William T. Barry ◽  
Chau T. Dang ◽  
Denise A. Yardley ◽  
Beverly Moy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Her2 Positive ◽  
Node Negative ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer

2021 ◽  
pp. 156-159
Author(s):  
M. A. Frolova ◽  
M. B. Stenina
Keyword(s):  
Breast Cancer ◽  
Treatment Options ◽  
Migration And Invasion ◽  
Line Treatment ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Wide Range ◽  
Positive Breast Cancer

In recent years, there has been a wide range of treatment options for patients with metastatic HER2-positive breast cancer, resulting in  the  highest life expectancy for  these patients among all subtypes. The  addition of  pertuzumab to trastuzumab and docetaxel has been shown to increase overall survival and is therefore recognized as the standard first-line treatment. The most optimal second-line treatment option is trastuzumab emtansine. In  addition, various combinations of  cytostatics and anti HER2 targeting agents can be used. The choice of treatment options in heavily pretreated patients is of great interest. If they have not previously received pertuzumab, is it worth to use it and which combination is the best? One possible option is the combination of eribulin with the dual anti-HER2 blockade with trastuzumab and pertuzumab. Eribulin is an anti-microtubule agent that irreversibly blocks mitosis. In addition, it has non-mitotic effects – in vivo and in vitro experiments demonstrated its ability to restore normal tumor vascularization, reduce the area of hypoxia and, as a consequence, decrease tumor cells migration and invasion. This article represents a clinical case of the use of eribulin with double anti-HER2 blockade in the 6th line of treatment in a patient with metastatic HER2-positive breast cancer. Long-term control of the disease (within 2 years) with a satisfactory quality of life has been demonstrated. 

scholarly journals Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer

2019 ◽  
Vol 17 (1) ◽  
pp. 47-56 ◽  
Author(s):  
Zachary Veitch ◽  
Omar F. Khan ◽  
Derek Tilley ◽  
Domek Ribnikar ◽  
Xanthoula Kostaras ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Real World ◽  
Her2 Positive ◽  
Node Negative ◽  
Node Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?

2020 ◽  
Vol 20 (6) ◽  
pp. 503-510
Author(s):  
Haiping Lin ◽  
Hongjuan Zheng ◽  
Chenyang Ge ◽  
Qinghua Wang ◽  
Wanfen Tang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Treatment ◽  
Her2 Positive ◽  
Node Negative ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

Breast Care ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. 168-171 ◽  
Author(s):  
Elena Laakmann ◽  
Volkmar Müller ◽  
Marcus Schmidt ◽  
Isabell Witzel
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Cytotoxic Agents ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Background: The incidence of brain metastases (BM) in breast cancer patients has increased. Many retrospective analyses have shown that first-line treatment with trastuzumab prolongs survival in patients with HER2-positive BM. In contrast, the evidence for other therapies targeting HER2 for patients with BM is rare. Methods: The aim of this review is to update the reader about current systemic treatment options in patients with HER2-positive metastatic breast cancer with BM who had already received trastuzumab. A literature search was performed in the PubMed database in June 2016. 30 relevant reports concerning the efficacy of trastuzumab emtansine (T-DM1), lapatinib and its combination with other cytotoxic agents, pertuzumab and novel HER2-targeting substances were identified. Results: There is limited but promising evidence for the use of T-DM1 and pertuzumab in the treatment of BM. Up to now, most reported studies used lapatinib as treatment of HER2-positive breast cancer with BM, a treatment with only a modest effect and a high toxicity profile. The combination of lapatinib with cytotoxic agents seems to result in better response rates. Conclusion: Further prospective investigations are needed to investigate the efficacy of the established and novel HER2-targeting agents on BM in HER2-positive breast cancer patients.

Locoregional Recurrence and Survival Outcomes by Type of Local Therapy and Trastuzumab Use Among Women with Node-Negative, HER2-Positive Breast Cancer

2014 ◽  
Vol 21 (11) ◽  
pp. 3490-3496 ◽  
Author(s):  
David J. Peterson ◽  
Pauline T. Truong ◽  
Betro T. Sadek ◽  
Cheryl S. Alexander ◽  
Bradley Wiksyk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Locoregional Recurrence ◽  
Local Therapy ◽  
Survival Outcomes ◽  
Her2 Positive ◽  
Node Negative ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document